Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System
Federal Register notice from the Federal Register
Headline as published by Federal Register: FDA on Oct 6, 2026; collected by the wire Oct 6, 2026, 6:15 AM ET.
The Food and Drug Administration (FDA) is classifying the high throughput DNA sequencing for hereditary cancer predisposition assessment test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the high throughput DNA sequencing for hereditary cancer predisposition assessment test system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the…
Coverage
Named in this story
- AgencyU.S. Food and Drug AdministrationMatched on
Food and Drug Administration
Topics
- Drugs and medical devicesMatched on
Medical Devices
Explore the named firms, organizations and MDL dockets above. Sources and method